On Tuesday, Shares of 3M Co (NYSE:MMM), lost -0.57% to $157.75.
3M Company operates as a diversified technology company worldwide. Its Industrial segment offers tapes; coated, non-woven, and bonded abrasives; adhesives; ceramics; sealants; specialty materials; filtration products; closure systems for personal hygiene products; acoustic systems products; automotive components; abrasion-resistant films; structural adhesives; and paint finishing and detailing products.
When research and development is the heartbeat of a company, innovation is bound to follow. Thomson Reuters recognized the creative innovations that take place at 3M every day and has placed the science-based company high on its fifth annual Top 100 Global Innovators list. From a pool of more than 1,300 companies, 3M proved once again it is one of the best in the world when it comes to applying science to solve problems and improve lives around the world.
“3M is built on innovation; its future will be too,” said Ashish Khandpur, senior vice president, Research and Development, and chief technology officer. “We constantly make investments to strengthen our scientific capabilities and improvement our competitiveness to serve our customers and the broader society.”
3M strengths comprised all four principal criteria: overall patent volume, patent application-to-grant success rate, global reach of the portfolio, and patent influence as evidenced by citations. Its highest score was in the Globalization category, where Thomson Reuters recognized the company’s strong emphasis on protecting its patents and innovations around the world.
Fair child Semiconductor International, Inc. designs, develops, manufactures, and markets power analog, power discrete, and non-power semiconductor solutions worldwide. It operates through three segments: Mobile, Computing, Consumer, and Communication (MCCC); Power Conversion, Industrial, and Automotive (PCIA); and Standard Discrete and Standard Linear (SDT).
Shares of Exelixis, Inc. (NASDAQ:EXEL), inclined -0.90% to $5.50, during its last trading session.
Exelixis, declared the presentation of positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating COTELLIC™ (cobimetinib) in patients with formerly untreated resectable, locally advanced or metastatic melanoma carrying a BRAF V600E or V600K mutation, in combination with vemurafenib. Dr. Victoria Atkinson, Medical Oncologist at Princess Alexandra Hospital, Queensland, Australia, presented the data during a late-breaking abstract oral presentation this afternoon at the Society for Melanoma Research (SMR) 2015 International Congress, which is being held November 18-21 in San Francisco. COTELLIC is a selective inhibitor of MEK that was discovered by Exelixis and is now the subject of a worldwide partnership agreement between Exelixis and Genentech, a member of the Roche Group.
In October 2015, Exelixis declared the coBRIM trial met its OS secondary endpoint, demonstrating a statistically noteworthy improvement in OS for the combination of COTELLIC and vemurafenib contrast to vemurafenib monotherapy. Recently’s presentation was the first to comprise detailed data on the endpoint. The median OS was 22.3 months for the combination of COTELLIC and vemurafenib as compared to 17.4 months for vemurafenib alone, corresponding to a 30% reduction in the rate of death for the combination as contrast to vemurafenib alone (hazard ratio [HR]=0.70, 95% confidence interval [CI] 0.55-0.90, p= 0.005). Ongoing study monitoring did not identify any new safety signals.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Finally, Shares of Atlas Resource Partners, L.P. (NYSE:ARP), ended its last trade with 5.96% gain, and closed at $1.60.
Atlas Energy Group, LLC (ATLS) and Atlas Resource Partners, L.P. (ARP), declared the appointment of Matthew Skelly as Vice President of Investor Relations of both ATLS and ARP.
Mr. Skelly has been with the Atlas companies for over five and a half years, formerly serving as the Vice President of Investor Relations for Atlas Pipeline Partners, L.P. starting in 2010 through its merger with Targa Resources in February 2015. Mr. Skelly formerly worked at the investment bank of JPMorgan covering financial institutions with a focus on the bank & thrift sector. Preceding to JPMorgan, Mr. Skelly was a senior advisor at Taylor Rafferty, focusing on cross-border investor relations consulting and capital markets intelligence to over 70 non-U.S. public companies. Mr. Skelly earned his Bachelor’s degree in Finance & Marketing from the University of South Carolina and his MBA in International Business from the Thunderbird School of Global Administration.
Atlas Resource Partners, L.P. operates as an independent developer and producer of natural gas, crude oil, and natural gas liquids in the United States. The company operates in three segments: Gas and Oil Production, Well Construction and Completion, and Other Partnership Administration. As of May 18, 2015, it owned interest in about 14,000 producing natural gas and oil wells located primarily in Appalachia, the Barnett Shale and the Eagle Ford Shale (Texas), the Mississippi Lime (Oklahoma), the Raton Basin (New Mexico), Black Warrior Basin (Alabama), and the Rangely Field (Colorado).